News J&J hopes FDA cardio label will limit Invokana damage Diabetes drug has been hit by amputation warning on label.
News FDA rejects J&J's sirukumab RA drug The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to evaluate its safety.
News AZ talks up Bydureon data, GLP-1 and glucagon combo AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug.
News FDA puts hold on AZ and Celgene immunotherapy trials Regulator is exploring safety of immunotherapy combinations in blood cancer
News FDA halts recruitment to three BMS Opdivo trials FDA is investigating safety of immunotherapies in blood cancer.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.